Table I.
Correlation between PD-L1 or PD-L2 protein expression in ENKL tissues and the clinicopathological parameters of the 30 ENKL patients.
| PD-L1, n | PD-L2, n | ||||||
|---|---|---|---|---|---|---|---|
|
|
|
||||||
| Variables | Total, n | − | + | P-value | − | + | P-value |
| Gender | |||||||
| Male | 21 | 10 | 11 | 0.193 | 8 | 13 | 0.804 |
| Female | 9 | 2 | 7 | 3 | 6 | ||
| Age, years | |||||||
| ≥45 | 17 | 7 | 10 | 0.880 | 6 | 11 | 0.858 |
| <45 | 13 | 5 | 8 | 5 | 8 | ||
| PS score | |||||||
| ≤80 | 15 | 7 | 8 | 0.456 | 5 | 10 | 0.705 |
| >80 | 15 | 5 | 10 | 6 | 9 | ||
| IPI score | |||||||
| ≤2 | 20 | 11 | 9 | 0.018 | 8 | 12 | 0.592 |
| >2 | 10 | 1 | 9 | 3 | 7 | ||
| Stage | |||||||
| I+II | 21 | 11 | 10 | 0.034 | 11 | 10 | 0.006 |
| III+IV | 9 | 1 | 8 | 0 | 9 | ||
| LDH | |||||||
| <281 | 23 | 12 | 11 | 0.014 | 10 | 13 | 0.161 |
| ≥281 | 7 | 0 | 7 | 1 | 6 | ||
| β2-MG | |||||||
| <3 | 20 | 9 | 11 | 0.429 | 7 | 13 | 0.789 |
| ≥3 | 10 | 3 | 7 | 4 | 6 | ||
| EBER | |||||||
| Positive | 25 | 9 | 16 | 0.317 | 8 | 17 | 0.236 |
| Negative | 5 | 3 | 2 | 3 | 2 | ||
| Ki-67, % | |||||||
| <60 | 15 | 9 | 6 | 0.025 | 5 | 10 | 0.705 |
| ≥60 | 15 | 3 | 12 | 6 | 9 | ||
PD-L, programmed death ligand; ENKL, extranodal natural killer/T-cell lymphoma, nasal type; PS, performance status; IPI, international prognostic index; LDH, lactate dehydrogenase; β2-MG, β2-microglobulin; EBER, Epstein-Barr virus-encoded small RNA.